Alliance Pharma (Alliance), a bioanalytical and CMC testing services firm in the pharmaceutical and biopharmaceutical industry, announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.
What were the executive’s thoughts on expansion?
Alliance’s opening of the Australian site closely follows their recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC. “With the speed to start Phase I studies, quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” commented Alliance CCO Vito Saccente.
“Alliance will not only be able to provide services critical to this market, but also when these compounds move to Phase II, we are well-positioned to transfer methods without losing critical knowledge and can support the progression of clinical development for our clients.”
What does the expansion mean for the region?
Alliance Pharma Pty, Ltd. will contain a state-of-the-art lab, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will now also be able to transfer methods and maintain continuous project management across their global bioanalytical sites in the US and Europe.
Alliance President Hao (Jason) Wang, Ph.D., will lead an experienced team of scientists to provide broad range bioanalytical services. This lab is outfitted with the latest LC-MS, ligand binding, flow cytometry, ELISpot and PCR instrumentation to support early and late phase research and will be capable of de novo method development, method transfers, method validation and sample analysis for pharmacokinetic (PK), biomarkers and immunogenicity.
